rp1954 wrote:I certainly would be interested to see the series of markers, inflammation markers and cytokines that you have to date vs doses.
We have very little inflammation data presented as yet, and Block Center certainly could use more definition as an option here.
As for adjuncts for BRAFv600 I might try to couple basic data from Block with perhaps more frequent interval data with generation of news options or leads to see effects if possible.
I'm a little hazy on how tight the Block blood are run - not having been there.
I think my reply did not go through. If you want to message me your email, I will gladly share a copy of his entire terrain panel and blood markers. I have an appointment with Block in a week. Like an oncologist prescribes an upfront megadose chemo protocol, ie: Folfoxiri+Avastin, Block has a core regimen of infusions and supplements, for stage 4. As treatments start lessening disease burden, ie: good response, he tends to tweak these treatments based on terrain, bloods and a bit of patient advocacy. He closely monitors immune function, which is factored in as well. The idea of signal analysis and N=1, as you have demonstrated is my aim. Precision medicine, if you will. This pivotal point for us will provide a lot of information on how the residual disease will function. Up front, I would like to be proactive and avoid being reactive at all cost. I'm interested in hearing your methods of analyzing your wife's cancer behavior, through chosen blood markers correlate to the mechanisms of action in each supplement choice, while on chronomodulated Xeloda. I can take a guess, but precision is the key. Reversing the dysfunction in cell signaling, or engaging the immune system to do so, while making strategic moves, is my ultimate goal.
I know this is a lot, but I believe in your ability to shed light on this.
Also, I do believe Block feels as if he is able to determine inflammation based on his terrain. I can clarify if you'd like to see it. Of course, additional advice or input is ALWAYS welcome.